An interventional study of Cohort 1 Intervention group and Cohort 2 severe/CIS margins clear in Oral Epithelial Dysplasia (OED) and Oral Squamous Cell Carcinoma (SCC), sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada — 30 open to participants now, 57 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Canada.
Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, this one is the 18th largest by planned enrollment of the 149 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, reaches primary completion later than 56 of the 56 other live ones, and was the 158th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →30 of the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Canada, United States, Austria and 11 more countries
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Canada, United States, Japan and 1 more country
Ages 18+
AbbVie · Sites in Canada, United States, Israel and 1 more country
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 61 · Phase 3 39 · Phase 4 1
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 636 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 129 across the 149 interventional studies, 35 across the 9 observational. Of the 100 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 164 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,340 studies on the registry; 260 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
16 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT06578871London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSurgery and Reducing Ionizing Radiation of the Unknown Primary | 2026-12-31 |
| NCT05941507LigaChem Biosciences, Inc.A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to optimize treatment strategies for patients with p53-mutant oral epithelial dysplasia (OED) and early-stage oral squamous cell carcinoma (OSCC). The main question it aims to answer is what the most optimal treatment is at each diagnostic stage. It is hypothesized that lesions with p53-abnormal low-grade dysplasia (LGD) without surgical intervention will progress to high-grade dysplasia (HGD) or SCC in 4 years. It is also predicted that a clear p53 and severe/CIS excision margins in patients with p53-abnormal HGD will reduce the progression to invasive SCC, compared to clear severe/CIS margins, within 4 years. Finally, it is thought that patients with p53-abnormal cT1N0 and DOI\<4mm receiving an END will have improved disease free and overall survival. This research will elucidate whether or not these hypotheses are correct.
Participants in each diagnostic cohort will be assigned to one of two different treatment options, listed below:
Cohort 1:
A) No intervention, observation only B) Surgical excision with clear margins
Cohort 2:
A) Surgical excision with clear severe/CIS margins B) Surgical excision with clear severe/CIS and p53 margins
Cohort 3:
A) Surgical excision and elective neck dissection (END) B) Surgical excision and close follow-up, only salvage ND if development of nodal disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1:
Cohort 2:
Cohort 3:
Exclusion Criteria:
Cohort 1:
Cohort 2:
Cohort 3:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observation only
Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins
Procedure: Cohort 1 Intervention group
Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear
Procedure: Cohort 2 severe/CIS margins clear
Excision of the lesion ensuring final negative p53 and severe/CIS margins
Procedure: Cohort 2 p53 and severe/CIS margins clear
Excision of primary lesion and immediate elective neck dissection (END)
Procedure: Cohort 3 Excision and END
Excision of primary lesion and close follow up with salvage neck dissection if development of nodal disease
Procedure: Cohort 3 Excision and Close follow up
Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins.
Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear
Excision of the lesion ensuring final negative p53 and severe/CIS margins
Excision of primary lesion and immediate elective neck dissection
Excision of primary lesion and close follow up with salvage neck dissection if development of nodal disease
Progression of Disease
Study 1: Whether diagnosis progressed from low-grade dysplasia (mild/moderate OED) to high-grade (severe/CIS) dysplasia or OSCC. Study 2: Whether diagnosis progressed from high-grade (severe/CIS) dysplasia to OSCC.
Time frame: 4 years
Time of Disease Progression
Study 1: Time for disease to progress from low-grade dysplasia (mild/moderate OED) to high-grade (severe/CIS) dysplasia or OSCC. Study 2: Time for disease to progress from high-grade (severe/CIS) dysplasia to OSCC.
Time frame: 4 years
Recurrence of Disease
Study 1: Whether recurrence of low-grade dysplasia is present. Study 2: Whether recurrence of high-grade dysplasia is present. Study 3: Whether recurrence of OSCC is present, and if recurrence pattern is local recurrence or nodal metastasis. All: Time for disease to recur.
Time frame: Study 1 and 2: 4 years, Study 3: 3 years
Disease-free Survival
Study 3: If survival is achieved disease-free following treatment.
Time frame: 3 years
Overall survival
Overall survival is measured as survival for 4 years following diagnosis and treatment. Cause of death will be included, if applicable.
Time frame: Study 1 and 2: 4 years, Study 3: 3 years
Patient Reported Outcomes - Quality of Life and Functional Measurements
Patient quality of life: 1. Oral Health Impact Profile-14 (OHIP) - 14 questions on a 5 point Likert scale (0-4), total ranging from 0-56, with higher scores indicating worse quality of life. 2. Hospital Anxiety and Depression Scale (HADS) - 14 questions on a 4 point Likert scale (0-3), total ranging from 0-21, with higher scores indicating increased severity or probability of depression and anxiety. Functional measurement: 1\. MD Anderson Dysphagia Inventory (MDADI) - 20 questions on a 5 point Likert scale (1-5), score total ranging from 20-100, with lower scores indicating more severe limitations.
Time frame: Study 1 and 2: 4 years, Study 3: 3 years
Plan to share: Undecided
Started Jul 2026 (actual). Primary completion is estimated for Jan 2032, 66 months after the start.
Of 115 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 66 months is above that.
Counting every sponsor, half of 126 studies reached it within 59 months; a quarter within 34 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
University of British Columbia →